BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact - PubMed (original) (raw)
. 2008 Oct 7;105(40):15517-22.
doi: 10.1073/pnas.0807841105. Epub 2008 Oct 1.
Jenni E Crowley, Mary M Tomayko, Natalie Steinel, Patrick J O'Neill, William J Quinn 3rd, Radhika Goenka, Juli P Miller, Yun Hee Cho, Vatana Long, Chris Ward, Thi-Sau Migone, Mark J Shlomchik, Michael P Cancro
Affiliations
- PMID: 18832171
- PMCID: PMC2563088
- DOI: 10.1073/pnas.0807841105
BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact
Jean L Scholz et al. Proc Natl Acad Sci U S A. 2008.
Abstract
We have used an inhibiting antibody to determine whether preimmune versus antigen-experienced B cells differ in their requisites for BLyS, a cytokine that controls differentiation and survival. Whereas in vivo BLyS inhibition profoundly reduced naïve B cell numbers and primary immune responses, it had a markedly smaller effect on memory B cells and long-lived plasma cells, as well as secondary immune responses. There was heterogeneity within the memory pools, because IgM-bearing memory cells were sensitive to BLyS depletion whereas IgG-bearing memory cells were not, although both were more resistant than naïve cells. There was also heterogeneity within B1 pools, as splenic but not peritoneal B1 cells were diminished by anti-BLyS treatment, yet the number of natural antibody-secreting cells remained constant. Together, these findings show that memory B cells and natural antibody-secreting cells are BLyS-independent and suggest that these pools can be separately manipulated.
Conflict of interest statement
Conflict of interest statement: M.P.C. was supported in part by a sponsored research agreement between Human Genome Sciences, Inc., and the University of Pennsylvania.
Figures
Fig. 1.
BLyS inhibition in vivo. (A) C57BL/6 mice were treated with 100 μg of anti-BLyS i.p. on days 0 and 5 and subsequently analyzed for serum BLyS (open bars) and anti-BLyS (filled bars). Each bar represents the average ± SD for at least three mice per time point. Untreated mice (n = 34) are shown at day 0. Combined data from three separate experiments are shown. (B) Numbers of splenic follicular (FO) B cells ± SD for the same mice shown in A.
Fig. 2.
Effects of BLyS inhibition on B1 subsets. (A) Gating scheme for identification of B2, B1a, and B1b cells in spleen (Upper) or peritoneal cavity (Lower). Lymphocyte-gated cells are further identified as B1a (CD5+ IgM+) or B2 (CD5− IgM+) as shown in left plots and histograms; in addition, B1a cells are CD23− (data not shown), whereas B2s are CD23+ and thus include late TR and FO B cells. B1b cells are CD5lo/− CD23− IgM+ Mac1+ as shown in right plots. (B) Numbers of splenic (Upper) and PerC (Lower) B2 and B1 cells. Cell numbers ± SD for three untreated mice (open bars) and three treated mice are shown. n.s., not significant. (C) Numbers of PC-specific antibody-producing cells in spleen and PerC of isotype control-treated (open symbols) or anti-BLyS-treated (filled symbols) mice at 10 and 21 days after treatment. Each symbol represents one mouse.
Fig. 3.
BLyS ablation does not alter NP-reactive memory B cells or LLPC generated in wild-type mice (Memory System 1). (A and B) Memory B cell analysis of C57BL/6 mice immunized with NP-CGG. Primary immunization was at day 0, anti-BLyS treatment was at day 56, and NP booster immunization was at day 77. Memory B cell numbers and IgG titers were assessed at day 84 for all mice including untreated and primed-only controls. NP-reactive memory B cells were identified according to the FACS gating scheme shown in A. After doublet discrimination, DAPI exclusion, and lymphocyte gating, memory B cells were phenotyped as CD4−CD8−Gr-1−B220+NP+. NT, not treated control. NP-reactive memory B cell numbers and high-affinity anti-NP IgG1 antibody titers, as assessed by ELISA, are shown in B. Each symbol in graphs represents an individual mouse, black lines represent means, and combined results from two separate experiments are shown. Symbols at the bottom indicate treatment given (+) or not given (−). (C) Number of NP-specific LLPC in the bone marrow of control mice or anti-BLyS-treated mice at 21 days after anti-BLyS treatment and 77 days after NP-CGG immunization. Phenotyping strategy for LLPC is presented in
Fig. S4
.
Fig. 4.
Memory B cells generated in adoptive transfer systems are more resistant to BLyS depletion than naïve B cells. Memory B cells were generated from mVh186.2 Tg (Memory System 2; A and B) or Vh186.2 KI (Memory System 3; C, E, and F) donor B cells after adoptive transfer into AM14/Vκ8R double Tg mice and subsequent immunization i.p. with NP-CGG in alum. Naïve controls were unimmunized Vh186.2 KI donor strain (D and E) and recipient IgMa non-NIP-binding (A–C and E) B cells. Recipient mice >12 weeks after immunization and unimmunized donor strain controls were treated with two 100-μg i.p. doses of anti-BLyS (10F4) or hamster IgG isotype control (IC). Fifteen days later, spleens were harvested and analyzed by FACS. (A) Memory System 2. Single, live lymphocytes were identified by FSC and SSC profiles and EMA exclusion. Upper and Lower represent isotype control (IC) versus anti-BLyS-treated animals, respectively. NIP+ IgMa+ B cells were NP-specific donor-derived memory cells. NIP− IgMa+ B cells were recipient AM14/Vκ8R specificity naïve B cells. IgMa− IgMb+ B cells were non-Tg-bearing recipient B cells. This population is expanded in aged recipient mice and may represent endogenous memory B cells. Representative FACS plots are shown. (B) Total numbers of B cells in each subgroup were calculated from live splenocyte counts and FACS-based frequencies as shown in A. Each point represents an individual animal. Average fold depletion in anti-BLyS-treated (circles) versus isotype control-treated (triangles) animals is indicated. One-way Student's t tests were performed. n.s., not significant. **, P ≤ 0.01; ***, P < 0.001. (C) Memory System 3. Live lymphocytes were identified as in A. NIP+ κlow B cells were NP-specific donor-derived memory cells. NIP− B cells were recipient-derived naïve cells. Memory B cells were fractionated into IgG1-switched and nonswitched B cells. (D) Naïve controls for Memory System 3. Spleens were harvested from unimmunized Vh186.2 KI donor-strain mice. Live lymphocytes were gated as described in A. (E and F) Total numbers of B cells from each System 3 subgroup were calculated from live splenocyte counts and FACS-based frequencies.
Similar articles
- BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells.
Treml LS, Crowley JE, Cancro MP. Treml LS, et al. Semin Immunol. 2006 Oct;18(5):297-304. doi: 10.1016/j.smim.2006.07.001. Epub 2006 Aug 17. Semin Immunol. 2006. PMID: 16919470 Review. - Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response.
Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Do RK, et al. J Exp Med. 2000 Oct 2;192(7):953-64. doi: 10.1084/jem.192.7.953. J Exp Med. 2000. PMID: 11015437 Free PMC article. - Immune complex-mediated enhancement of secondary antibody responses.
Goins CL, Chappell CP, Shashidharamurthy R, Selvaraj P, Jacob J. Goins CL, et al. J Immunol. 2010 Jun 1;184(11):6293-8. doi: 10.4049/jimmunol.0902530. Epub 2010 May 3. J Immunol. 2010. PMID: 20439912 - Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model.
Bath NM, Ding X, Verhoven BM, Wilson NA, Coons L, Sukhwal A, Zhong W, Redfield Iii RR. Bath NM, et al. PLoS One. 2019 Oct 24;14(10):e0223889. doi: 10.1371/journal.pone.0223889. eCollection 2019. PLoS One. 2019. PMID: 31647850 Free PMC article. - The BLyS family: toward a molecular understanding of B cell homeostasis.
Treml JF, Hao Y, Stadanlick JE, Cancro MP. Treml JF, et al. Cell Biochem Biophys. 2009;53(1):1-16. doi: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26. Cell Biochem Biophys. 2009. PMID: 19034695 Free PMC article. Review.
Cited by
- Clinical outcomes in lupus nephritis patients treated with belimumab in real-life setting: a retrospective comparative study in China.
Lin Z, Jiang B, Wang W, Chen C, Wang Y, Wan J, Xu Y. Lin Z, et al. PeerJ. 2024 Sep 19;12:e18028. doi: 10.7717/peerj.18028. eCollection 2024. PeerJ. 2024. PMID: 39308826 Free PMC article. - Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis.
Zhao L, Wang W, Wu L, Wu T, Tu J, Wu X, Sun F, Ding H, Shen N, Wu H, Zhu J, Sun L, Ye S. Zhao L, et al. Lupus Sci Med. 2024 May 28;11(1):e001156. doi: 10.1136/lupus-2024-001156. Lupus Sci Med. 2024. PMID: 38806217 Free PMC article. - NF-kB's contribution to B cell fate decisions.
Guldenpfennig C, Teixeiro E, Daniels M. Guldenpfennig C, et al. Front Immunol. 2023 Jul 18;14:1214095. doi: 10.3389/fimmu.2023.1214095. eCollection 2023. Front Immunol. 2023. PMID: 37533858 Free PMC article. Review. - Efficacy and Safety of Belimumab in Lupus Nephritis Patients: A Real-World Observational Study in China.
Tan M, Xu J, Tan Y, Qu Z, Yu F, Zhao M. Tan M, et al. Kidney Dis (Basel). 2023 Feb 14;9(3):218-228. doi: 10.1159/000529675. eCollection 2023 May. Kidney Dis (Basel). 2023. PMID: 37497208 Free PMC article. - TRAF3-EWSR1 signaling axis acts as a checkpoint on germinal center responses.
Li Y, Zhu L, Ko CJ, Yang JY, Wang H, Manyam G, Wang J, Cheng X, Zhao S, Jie Z. Li Y, et al. J Exp Med. 2023 Aug 7;220(8):e20221483. doi: 10.1084/jem.20221483. Epub 2023 Apr 25. J Exp Med. 2023. PMID: 37097293 Free PMC article.
References
- Zubler RH. Naive and memory B cells in T-cell-dependent and T-independent responses. Springer Semin Immunopathol. 2001;23:405–419. - PubMed
- Schittek B, Rajewsky K. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors. Nature. 1990;346:749–751. - PubMed
- Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: A key to immune defense against pathogen invasion. Springer Semin Immunopathol. 2005;26:347–362. - PubMed
- Kalled SL, Ambrose C, Hsu YM. The biochemistry and biology of BAFF, APRIL, and their receptors. Curr Dir Autoimmun. 2005;8:206–242. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- T32 AI055428/AI/NIAID NIH HHS/United States
- A143603/PHS HHS/United States
- T32 AR007016/AR/NIAMS NIH HHS/United States
- R01 AI054488/AI/NIAID NIH HHS/United States
- R01 AI073939/AI/NIAID NIH HHS/United States
- AI073939/AI/NIAID NIH HHS/United States
- T32 AI-055428/AI/NIAID NIH HHS/United States
- AI054488/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources